Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gilead Sciences Inc.

www.gilead.com

Latest From Gilead Sciences Inc.

NICE Explains Its UK Funding Recommendation For Kymriah

The final appraisal document published today by the health technology assessment body NICE provides more insight into the health technology assessment body’s recent recommendation on Kymriah’s use in young people with leukemia.

US Drug Pricing Reforms Testing Limits Of Executive Action

Congressional inaction on drug pricing legislation has meant the Trump Administration is pursuing a menu of regulatory approaches. For the most part, that means slower and incremental change.

 

United States Pricing Strategies

CAR-T Label Update Could Address Medicare Coverage Challenges, FDA’s Gottlieb Suggests

Medicare’s current approach to inpatient CAR-T reimbursement in 2019 would lead to an $186,500 shortfall for providers per patient, stakeholders estimate.

Regulation Medicare

Express Scripts New Flex Formulary Will Prefer Lower-Priced Brand Alternatives

Gilead’s authorized generics for Epclusa and Harvoni will be first alternatives to benefit from preferred coverage on the pharmacy benefit manager's National Preferred Flex Formulary.

Pricing Strategies Market Access
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register